A Phase I/II Study of G3139 [oblimersen], a BCL-2 Antisense Oligonucleotide, Combined With Paclitaxel for the Treatment of Recurrent Small Cell Lung Cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Oblimersen; Paclitaxel
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Feb 2013 Biomarkers information updated
- 27 Sep 2005 New trial record.